Inventor · disambiguated record
Pericles Calias
Also filed as: CALIAS PERICLES
29 granted patents·27 pending applications·464 citations·filing 1999–2025
97Inventor score
Files withSHIRE HUMAN GENETIC THERAPIES19TAKEDA PHARMACEUTICALS CO7GENZYME CORP6CALIAS PERICLES4IMOTIK BIOSOLUTIONS LLC3
Top patents by PatentIndex Score
56 records- 0198US6521223B1Single phase gels for the prevention of adhesionsGENZYME CORP·Filed 2000·Granted Feb 18, 2003·206 cites·15 claims
- 0293US2025161417A1Methods and compositions for cns delivery of arylsulfatase aTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 0393US2025121040A1Methods and compositions for cns delivery of iduronate-2-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 0492US9220677B2Methods and compositions for CNS delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Dec 29, 2015·16 cites·27 claims
- 0592US8545837B2Methods and compositions for CNS delivery of iduronate-2-sulfataseZHU GAOZHONG·Filed 2011·Granted Oct 1, 2013·38 cites·30 claims
- 0692US2025375506A1Cns delivery of therapeutic agentsTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 0791US11065308B2Methods and compositions for CNS delivery of heparan n-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2018·Granted Jul 20, 2021·6 cites·5 claims
- 0891US10456454B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Oct 29, 2019·6 cites·27 claims
- 0991US9283181B2CNS delivery of therapeutic agentsCALIAS PERICLES·Filed 2011·Granted Mar 15, 2016·34 cites·6 claims
- 1090US10660944B2Stable formulations for CNS delivery of arylsulfatase ASHIRE HUMAN GENETIC THERAPIES·Filed 2018·Granted May 26, 2020·5 cites·23 claims
- 1190US6749865B2Modification of biopolymers for improved drug deliveryGENZYME CORP·Filed 2001·Granted Jun 15, 2004·26 cites·16 claims
- 1289US11471516B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Oct 18, 2022·1 cites·17 claims
- 1389US9814764B2Treatment of sanfilippo syndrome type b by intrathecal administration of alpha-n-acetylglucosaminidaseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Nov 14, 2017·9 cites·20 claims
- 1488US6610669B1Water insoluble derivatives of polyanionic polysaccharidesGENZYME CORP·Filed 1999·Granted Aug 26, 2003·53 cites·23 claims
- 1586US11260112B2Methods and compositions for CNS delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Mar 1, 2022·2 cites·17 claims
- 1686US9320711B2Methods and compositions for CNS delivery of heparan N-sulfataseNATOLI FARAH·Filed 2011·Granted Apr 26, 2016·22 cites·43 claims
- 1785US12409210B2CNS delivery of therapeutic agentsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Sep 9, 2025·0 cites·5 claims
- 1883US11065307B2Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moietySHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted Jul 20, 2021·2 cites·8 claims
- 1983US7456220B2Immunodulatory compositions and methods of use thereofGENZYME CORP·Filed 2005·Granted Nov 25, 2008·2 cites·1 claims
- 2082US7189413B2Drug delivery of proteins from polymeric blendsGENZYME CORP·Filed 2002·Granted Mar 13, 2007·11 cites·23 claims
- 2181US12121569B2Methods and compositions for CNS delivery of iduronate-2-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Oct 22, 2024·0 cites·15 claims
- 2281US8945542B2Methods for treating lysosomal acid lipase deficiencySYNAGEVA BIOPHARMA CORP·Filed 2013·Granted Feb 3, 2015·8 cites·3 claims
- 2380US9770410B2Methods and compositions for CNS delivery of arylsulfatase ASALAMAT-MILLER NAZILA·Filed 2011·Granted Sep 26, 2017·10 cites·32 claims
- 2479US12161702B2Methods and compositions for CNS delivery of heparan N-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Dec 10, 2024·0 cites·19 claims
- 2575US12168041B2Methods and compositions for CNS delivery of arylsulfatase ATAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Dec 17, 2024·0 cites·6 claims
- 2673US10646554B2Methods and compositions for CNS delivery of arylsulfatase ASHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted May 12, 2020·0 cites·19 claims
- 2771US11504515B2Access port system with self-adjusting catheter lengthIMOTIK BIOSOLUTIONS LLC·Filed 2019·Granted Nov 22, 2022·2 cites·14 claims
- 2870US2024335647A1Access port system with self-adjusting catheter lengthIMOTIK BIOSOLUTIONS LLC·Filed 2024·Application pending·0 cites
- 2969US11986616B2Access port system for intrathecal drug delivery with self-adjusting catheter lengthIMOTIK BIOSOLUTIONS LLC·Filed 2022·Granted May 21, 2024·0 cites·13 claims
- 3068US2022354968A1Mrna therapy for the treatment of ocular diseasesTRANSLATE BIO INC·Filed 2022·Application pending·0 cites
- 3164US2025154203A1Method of producing peptide derived from chaperonin 60.1REVOLO BIOTHERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 3263US2017042977A1Methods and compositions for cns delivery of heparan n-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Application pending·0 cites
- 3362US2016158324A1Methods and compositions for cns delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Application pending·0 cites
- 3461US2020237883A1Stable formulations for cns delivery of arylsulfatase aSHIRE HUMAN GENETIC THERAPIES·Filed 2020·Application pending·0 cites
- 3559US2014377244A1Stable formulations for cns delivery of arylsulfatase aSHIRE HUMAN GENETIC THERAPIES·Filed 2012·Application pending·0 cites
- 3658US2015037429A1Controlled Release MicroparticlesVALEANT PHARMACEUTICALS INT·Filed 2014·Application pending·0 cites
- 3752US2022133863A1Treatment of sanfilippo syndrome type bSHIRE HUMAN GENETIC THERAPIES·Filed 2021·Application pending·0 cites
- 3852US2017143848A1Mrna therapy for the treatment of ocular diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Application pending·0 cites
- 3950US2018036386A1Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiiaSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 4048US2013295071A1Methods and compositions for cns delivery of b-galactocerebrosidaseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Application pending·0 cites
- 4148US2004230183A1Drug delivery device and syringe for filling the sameFiled 2004·Application pending·0 cites
- 4248US2015313971A1Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiiaSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Application pending·0 cites
- 4347US2022168301A1Methods for treating symptomatic orthostatic hypotensionCERECOR INC·Filed 2020·Application pending·0 cites
- 4446US7417021B2Biologically active conjugate of a biopolymer and therapeutic agentGENZYME CORP·Filed 2004·Granted Aug 26, 2008·5 cites·23 claims
- 4546US2015202292A1Electrochemically degradable polymersTRUSTEES OF TUFTS COLLEGE D B A TUFTS UNIVERSITY·Filed 2014·Application pending·0 cites
- 4644US2015175723A1Electrochemically degradable polymersCALIAS PERICLES·Filed 2013·Application pending·0 cites
- 4743US8877229B2Controlled release microparticlesCAMPBELL KATHLEEN M·Filed 2006·Granted Nov 4, 2014·0 cites·39 claims
- 4842US2005260153A1Facilitation of iontophoresis using charged moietiesCALIAS PERICLES·Filed 2005·Application pending·0 cites
- 4942US2016030416A1Methods of treating b2-bradykinin receptor mediated angioedemaSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Application pending·0 cites
- 5042US2005260651A1Enhanced biologically active conjugatesCALIAS PERICLES·Filed 2005·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Pericles Calias files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →